Argos Therapeutics, Inc. Stock

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

19-09-24	Argos Therapeutics, Inc. Went Out of Business	CI
19-09-24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 278K 256K 238K 452K 30.3M 458K 3.07M 1.19M 14.87M 1.19M 1.17M 51.56M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.02M 3.7M 3.43M 6.52M 437M 6.61M 44.27M 17.23M 215M 17.22M 16.84M 744M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Argos Therapeutics, Inc.

19-09-24	Argos Therapeutics, Inc. Went Out of Business	CI
19-09-24	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
19-08-30	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
19-03-21	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
19-03-15	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
19-02-12	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
19-01-22	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
19-01-21	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
19-01-21	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
19-01-21	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
18-12-20	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
18-12-06	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
18-12-03	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
REGENERON PHARMACEUTICALS, INC.	-0.68%	+2.85%	+18.72%	-7.81%	66.56B
UCB	-1.97%	-3.45%	+50.62%	+221.13%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	-1.13%	+40.50%	+40.50%	+40.50%	42.98B
CSL LIMITED	+0.12%	+8.32%	-49.88%	-53.43%	40.46B
BIOGEN INC.	-3.54%	-3.77%	+56.89%	-26.85%	31.91B
MODERNA, INC.	+2.56%	+17.36%	+168.28%	-30.85%	31.65B
INCYTE CORPORATION	-1.06%	+0.84%	+68.91%	+83.93%	23.35B
INNOVENT BIOLOGICS, INC.	-1.38%	+12.25%	+8.24%	+195.37%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	+0.21%	+3.76%	+66.67%	+133.69%	17.18B
Average	-0.68%	+4.21%	+47.66%	+61.74%	33B
Weighted average by Cap.	-0.85%	+3.91%	+42.07%	+53.87%

	2016	2017
Net sales	945K 828K 763K 708K 1.34M 90.19M 1.36M 9.13M 3.55M 44.27M 3.55M 3.47M 153M	1.9M 1.66M 1.53M 1.42M 2.7M 181M 2.74M 18.34M 7.14M 88.93M 7.13M 6.98M 308M
Net income	-53.03M -46.44M -42.78M -39.71M -75.4M -5.06B -76.42M -512M -199M -2.48B -199M -195M -8.61B	-40.58M -35.54M -32.73M -30.38M -57.7M -3.87B -58.48M -392M -152M -1.9B -152M -149M -6.59B
Net Debt	-13.11M -11.48M -10.57M -9.82M -18.64M -1.25B -18.89M -127M -49.26M -614M -49.23M -48.15M -2.13B	4.27M 3.74M 3.44M 3.2M 6.07M 407M 6.15M 41.21M 16.04M 200M 16.03M 15.67M 693M

Argos Therapeutics, Inc. Stock

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news : Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile